XBiotech: Rises on positive data from COVID-19 antibody study

XBiotech

19/11/2020 14:45

** Shares of drug developer  XBIT.O  rise 6.3% to $20.14
    ** XBIT reports new data demonstrating effective anti-virus
activity for its therapy for infections of influenza and
COVID-19  urn:newsml:reuters.com:*:nGNX375Dkx
    ** Co's data is from its True Human antibodies, which are
derived without modification from humans who possess natural
immunity to certain diseases 
    ** Says True Human antibodies effectively neutralized test
coronavirus at concentrations about four times better than
antibodies U.S. FDA is considering for emergency use
authorization 
    ** Up to last close, XBIT stock up 1.4% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132))